Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Evolving concepts in systemic lupus erythematosus damage assessment

An Author Correction to this article was published on 27 April 2021

This article has been updated

The Systemic Lupus International Collaborating Clinics–ACR Damage Index (SDI) has been widely used for 25 years. This index, however, has its limitations, providing a rationale for a global initiative to create a revised, updated SDI to capture organ damage across the age-spectrum.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The development of SLE and consequent accrual of organ damage.

Change history


  1. Strand, V. et al. Endpoints: consensus recommendations from OMERACT IV. Lupus 9, 322–327 (2000).

    Article  CAS  Google Scholar 

  2. Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363–369 (1996).

    Article  CAS  Google Scholar 

  3. Parker, B. & Bruce, I. N. in Dubois’ Lupus Erythematosus and Related Syndromes (eds D. J. Wallace & Hahn, B. H.) Ch. 49, 614–630 (2019).

  4. Barber, M. R. W. et al. Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. Arthritis Care Res. (Hoboken) 72, 1800–1808 (2019).

    Article  Google Scholar 

  5. Van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).

    Article  Google Scholar 

  6. Mahieu, M. A., Strand, V., Simon, L. S., Lipsky, P. E. & Ramsey-Goldman, R. A critical review of clinical trials in systemic lupus erythematosus. Lupus 25, 1122–1140 (2016).

    Article  CAS  Google Scholar 

  7. Touma, Z., Urowitz, M. B., Ibanez, D. & Gladman, D. D. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J. Rheumatol. 41, 688–697 (2014).

    Article  CAS  Google Scholar 

  8. Holland, M. J. et al. Measuring disease damage and its severity in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 70, 1621–1629 (2018).

    Article  Google Scholar 

  9. Sutton, E. J., Davidson, J. E. & Bruce, I. N. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin. Arthritis Rheum. 43, 352–361 (2013).

    Article  Google Scholar 

Download references


The authors acknowledge funding support from the Lupus Foundation of America and the ACR. INB is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Ian N. Bruce.

Ethics declarations

Competing interests

M.R.W.B has received consulting fees from Janssen and Sanofi Genzyme. S.R.J. has received consulting fees from Boehringer Ingelheim and Ikaria. D.D.G. has received grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, and consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. A.E.C. has received consulting fees from AstraZeneca, Exagen Diagnostics, BristolMyersSquibb and GSK. I.N.B. has received grant support from Genzyme/Sanofi, GSK, Roche and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, UCB and ILTOO; and was a speaker for AstraZeneca, GSK and UCB.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barber, M.R.W., Johnson, S.R., Gladman, D.D. et al. Evolving concepts in systemic lupus erythematosus damage assessment. Nat Rev Rheumatol 17, 307–308 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing